Optimized scaling of translational factors in oncology: from xenografts to RECIST

ConclusionsWe believe that given more data, our methodology could contribute to increasing the translational capabilities of TGI models. More specifically, an appropriate translational method could be developed for drugs with the same mechanism of action, which would allow for all preclinical data to be leveraged for new drugs of the same class. This would ensure that fewer clinically inefficacious drugs are tested in clinical trials.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research